Log In
BCIQ
Print this Print this
 

fasinumab (REGN475)

Also known as: formerly SAR164877

  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
Description mAb against nerve growth factor (NGF)
Molecular Target Nerve growth factor (NGF)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationPain
Indication DetailsTreat chronic low back pain; Treat moderate to severe osteoarthritis (OA) pain of the hip or knee; Treat pain associated with osteoarthritis (OA) of the knee
Regulatory Designation
PartnerMitsubishi Tanabe Pharma Corp.;
Teva Pharmaceutical Industries Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$2,935.0M

$305.0M

$2,360.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/20/2016

$2,610.0M

$250.0M

$2,360.0M

10/01/2015

$325.0M

$55.0M

Undisclosed

Get a free BioCentury trial today